Ebrima Gibbs
Overview
Explore the profile of Ebrima Gibbs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
323
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aina A, Hsueh S, Gibbs E, Peng X, Cashman N, Plotkin S
ACS Chem Neurosci
. 2023 Jul;
14(15):2603-2617.
PMID: 37458595
Tau pathology is associated with many neurodegenerative disorders, including Alzheimer's disease (AD), where the spatio-temporal pattern of tau neurofibrillary tangles strongly correlates with disease progression, which motivates therapeutics selective for...
2.
Gibbs E, Zhao B, Roman A, Plotkin S, Peng X, Hsueh S, et al.
Biomedicines
. 2022 Sep;
10(9).
PMID: 36140270
Misfolded toxic forms of alpha-synuclein (α-Syn) have been implicated in the pathogenesis of synucleinopathies, including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). The α-Syn...
3.
Li F, Liu A, Gibbs E, Tanunliong G, Marquez A, Gantt S, et al.
J Clin Virol
. 2021 Dec;
146:105050.
PMID: 34883405
Background: Multiplex immunoassays capture a comprehensive profile of the humoral response against SARS-CoV-2 and human endemic coronaviruses. We validated a multiplex panel (V-PLEX Panel 2) from Meso Scale Diagnostics targeting...
4.
Thebault S, Gibbs E, Bourque P, McKim D, Rakhra K, Breiner A, et al.
Neuromuscul Disord
. 2021 Oct;
31(12):1279-1281.
PMID: 34690051
Myasthenia gravis is a treatable autoimmune disease caused by autoantibodies directed against membrane proteins at the neuromuscular junction. While acetylcholine receptor antibodies are most common, a minority of patients have...
5.
Peng X, Gibbs E, Silverman J, Cashman N, Plotkin S
Stat Methods Med Res
. 2021 Apr;
30(6):1502-1522.
PMID: 33847541
Multiple different screening tests for candidate leads in drug development may often yield conflicting or ambiguous results, sometimes making the selection of leads a nontrivial maximum-likelihood ranking problem. Here, we...
6.
Jin J, Fan X, Del Cid-Pellitero E, Liu X, Zhou L, Dai C, et al.
Commun Biol
. 2021 Feb;
4(1):232.
PMID: 33608634
Convincing evidence supports the premise that reducing α-synuclein levels may be an effective therapy for Parkinson's disease (PD); however, there has been lack of a clinically applicable α-synuclein reducing therapeutic...
7.
Khorvash M, Blinov N, Ladner-Keay C, Lu J, Silverman J, Gibbs E, et al.
PLoS One
. 2020 May;
15(5):e0232266.
PMID: 32469918
Oligomeric amyloid β (Aβ) is currently considered the most neurotoxic form of the Aβ peptide implicated in Alzheimer's disease (AD). The molecular structures of the oligomers have remained mostly unknown...
8.
Zhao B, Marciniuk K, Gibbs E, Yousefi M, Napper S, Cashman N
Vaccine
. 2019 Jul;
37(35):4920-4927.
PMID: 31324499
Emerging evidence suggests seeding and prion-like propagation of mutant Superoxide Dismutase 1 (SOD1) misfolding to be a potential mechanism for ALS pathogenesis and progression. Immuno-targeting of misfolded SOD1 has shown...
9.
A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer's Disease
Gibbs E, Silverman J, Zhao B, Peng X, Wang J, Wellington C, et al.
Sci Rep
. 2019 Jul;
9(1):9870.
PMID: 31285517
Advances in the understanding of Alzheimer's disease (AD) suggest that pathogenesis is not directly related to plaque burden, but rather to soluble toxic amyloid-beta oligomers (AßO). Therapeutic antibodies targeting Aß...
10.
Cheng W, Martens K, Bashir A, Cheung H, Stukas S, Gibbs E, et al.
Alzheimers Res Ther
. 2019 Jan;
11(1):6.
PMID: 30636629
Background: The annual incidence of traumatic brain injury (TBI) in the United States is over 2.5 million, with approximately 3-5 million people living with chronic sequelae. Compared with moderate-severe TBI,...